Submitted by aml95 on Tue, 03/03/2026 - 15:53
Researchers in the Hovorka and Boughton groups at the IMS-MRL have carried out a retrospective observational analysis of data from over 35,000 people living with type 1 diabetes across 19 countries who use the CamAPS FX hybrid closed-loop system, in order to evaluate the performance of the system in a ‘real-world’ setting.
Published as the first research paper in the new journal, Metabologia, they report outcomes similar to those from previous randomised clinical trials, corroborating the performance of the closed-loop system in the real-world setting with most users able to meet recommended glucose targets as outlined by international guidelines (with some variability in glucose outcomes by age group and geography).
They found the average time in the target glucose range (3.9–10 mmol/l) was 70% for all users (this varied across the different age groups from 63% for young adult users aged 18–22 years old to 76% for users aged ≥ 65 years). The average time spent in hypoglycaemia (< 3.9 mmol/l) was 2.5% overall, and was < 4% across all age groups. The mean glucose and glucose management indicator overall were 8.7 mmol/l and 7.1% (53.6 mmol/mol), respectively. Average time in closed-loop was high at 96% which supports the acceptability and ease of use of the system.
Real-world evidence of the performance of commercially available hybrid closed-loop systems is essential to corroborate the findings reported in randomised controlled trials (RCTs), and to support widespread adoption and reimbursement. Real-world data has certain benefits over trial data with the inclusion of a much larger and more diverse demographic and geography, and much less restriction with regards to inclusion and exclusion criteria, and therefore outcomes may be more generalisable.
Reference: Boughton, C.K., Hovorka, T., Wilinska, M.E. et al. Real-world evidence on the CamAPS FX hybrid closed-loop system in people living with type 1 diabetes. Metabologia 2, 1 (2026). https://doi.org/10.1007/s44357-025-00002-2
